Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK Cells
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Basal Cell Carcinoma
Conditions
Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, Skin Squamous Cell Carcinoma
Trial Timeline
Oct 16, 2025 → Dec 31, 2026
NCT ID
NCT07144384About Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK Cells
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK Cells is a phase 1 stage product being developed by Johnson & Johnson for Skin Basal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07144384. Target conditions include Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, Skin Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07144384 | Phase 1 | Recruiting |
Competing Products
20 competing products in Skin Basal Cell Carcinoma